Roche Diagnostics Operations, Inc.

University of Toronto

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Liebherr-components Biberach Gmbh

Georg Hess

Andrea Horsch

Dietmar Zdunek

Hendrik Huedig

Ursula-Henrike Wienhues-Thelen

Dirk Block

Peter Liu

Andrew Emili

Herbert Von Der Eltz

Klaus Graner

Volker Klemt

David MacLennan

Thomas Kislinger

Ruth Isserlin

Vincent Fong

Rosemarie Kientsch-Engel

Andreas Gallusser

Anthony Gramolini

Thomas Schulze

Sara Arab

Sabine Vogel-Ziebolz

Andrea Hess

Hendrik Heudig

Christine Boehm

Hendrik Hudig

Christine Bohm

David Maclennan

Hendrik HÜDIG

Andreas Galluser

The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.

GDF-15 and/or troponin T for predicting kidney failure in heart surgery patients

Method for determination of whether a subject suffers from intermittent atrial fibrillation based on the determination of the amount of a Troponin T in a sample in a patient suffering from atrial fibrillation using a binding assay. Kits and devices adapted to carry out the methods are also provided.

Troponin and BNP based diagnosis of risk patients and cause of stroke

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.

Use of IGFBP-7 in the assessment of heart failure

Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.

Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure

The present invention relates to a method for diagnosing a transitory ischemic attack (TIA) in a subject who is suspected to have exhibited a transitory ischemic attack, but who did not exhibit a stroke. The method is based on the determination of the amount of NT-proANP in a sample from said subject. Moreover, the present invention is directed to a method for diagnosing an acute cerebral ischemic event in a subject based on the determination of the amounts of NT-proBNP and NT-proANP in a sample from a subject. The method further comprises the step of calculating a ratio of the amounts of NT-proBNP and NT-proANP. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.

NT-proANP and NT-proBNP for the diagnosis of stroke

The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.

Use of mimecan in the assessment of heart failure

The present invention relates to a method for identifying a subject being susceptible to anti-angiogenesis therapy based in determining the amount of a cardiac troponin in a sample of the subject and comparing the amount to a suitable reference amount. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.

Identification of subjects being susceptible to anti-angiogenesis therapy

The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient.

NT-pro ANP and SFlt-1 for the differentiation between circulatory and ischemic events

Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.

Prediction and recognition of acute kidney injury after surgery

The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.

Use of SLIM-1 in the assessment of heart failure

Disclosed is a method of determining which medication is to be applied in a remodeling process of a subject after a myocardial infarction, the method comprising determining an amount of a natriuretic peptide, a cardiac troponin, and an inflammatory marker in a sample from the subject and initiating a remodeling in the subject, wherein the medication to be applied in the remodeling is selected according to the level of the peptides determined. Also disclosed is a method of monitoring the remodeling, wherein further steps include again determining an amount of the natriuretic peptide, the cardiac troponin, and the inflammatory marker in a sample from the subject, calculating the difference between the values from the first and second measurements, and assessing remodeling success from the data obtained.

Monitoring myocardial infarction and its treatment

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.

Use of SFRP-3 in the assessment of heart failure

The present disclosure relates to a method for diagnosing the ischemic state in a subject suffering from acute coronary syndrome who does not fulfilling the diagnostic criteria for a myocardial infarction. The present disclosure also relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome but does not fulfill the diagnostic criteria for a myocardial infarction. The methods of the present disclosure are based on the determination of fms-like tyrosine kinase-1 (sFLT-1) and, optionally, hepatocyte growth factor (HGF) in a sample of said subject. The present disclosure also relates to kits and/or devices for carrying out the methods disclosed herein.

Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction

The present invention relates to a method of differentiating between a singular and a multiple lung embolism in a subject suspected to suffer from acute lung embolism comprising determining the amount of NT-proBNP in a sample of a subject suspected to suffer from acute lung embolism and comparing the amount to a reference amount. Further, the present invention also relates to a method of differentiating between acute and chronic lung embolism in a subject comprising determining the amount of NT-proANP at a first and a second time point and comparing the determined amounts with each other. The present invention also encompasses devices and kits for carrying out the aforementioned methods.

Growing community of inventors

Mainz, Germany

Georg Hess